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Background: To understand the contribution of Mendelian mutations to the burden of undiagnosed diseases that
are suspected to be genetic in origin, we developed a next-generation sequencing-based multiplexing assay that
encompasses the ~3000 known Mendelian genes. This assay, which we term the Mendeliome, comprises 13 gene
panels based on clinical themes, covering the spectrum of pediatric and adult clinical genetic medicine. We explore
how these panels compare with clinical whole exome sequencing (WES).
Results: We tested 2357 patients referred with suspected genetic diagnoses from virtually every medical specialty.
A likely causal mutation was identified in 1018 patients, with an overall clinical sensitivity of 43 %, comparing
favorably with WES. Furthermore, the cost of clinical-grade WES is high (typically more than 4500 US dollars),
whereas the cost of running a sample on one of our panels is around 75–150 US dollars, depending on the panel.
Of the “negative” cases, 11 % were subsequently found by WES to harbor a likely causal mutation in a known
disease gene (largely in genes identified after the design of our assay), as inferred from a representative sample of
178. Although our study population is enriched for consanguinity, 245 (24 %) of solved cases were autosomal
dominant and 35 (4 %) were X-linked, suggesting that our assay is also applicable to outbred populations.
Conclusions: Despite missing a significant number of cases, the current version of the Mendeliome assay can
account for a large proportion of suspected genetic disorders, and provides significant practical advantages over
clinical WES.Background
The contribution of genetic variation to human diseases
is an old concept, but its realization in the practice of
medicine has been challenging. For most diseases, the
genetic risk is both modest and strongly influenced by
environmental risk factors such that the medical action-
ability of the identified genetic risk is limited [1, 2]. On
the other hand, there are diseases that are traceable to
mutations in single genes. These so-called Mendelian
diseases offer a unique window into the physiological
role of individual genes across tissues and stages of de-
velopment [3]. From a clinical perspective, Mendelian
mutations are the most medically actionable genetic var-
iants in that they can be assigned a causal role with the
attendant management and prevention benefits.* Correspondence: falkuaya@kfshrc.edu.sa
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unless otherwise stated.Although the first Mendelian mutation was identi-
fied in the 1980s, less than 200 Mendelian genes were
known by the turn of the 21st century [4]. The publi-
cation of the human genome and the development of
new analytical tools to study it, primarily next-
generation sequencing (NGS), have sparked an unpre-
cedented race to identify the suspected thousands of
Mendelian genes, and as of the writing of this manu-
script, more than 3000 genes are listed in the Online
Mendelian Inheritance in Man (OMIM) database as
disease causing [5–7]. With the discovery of each
Mendelian gene, there is the immediate translational
benefit of offering a precise molecular diagnosis for
more patients and their families.
In order to reap the benefits of this growing know-
ledge of genes that cause human diseases in a Mendelian
fashion, genome sequencing tools have quickly been in-
troduced into the realm of clinical diagnostics [8]. Whilepen Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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comprehensive option, sequencing of its ~2 % coding
part (whole-exome sequencing [WES]) has emerged as
a cheaper and more practical alternative [9]. Applica-
tion of WES in the clinic to explain the etiology of
suspected Mendelian disorders has been relatively
successful. A few large studies on the clinical utility of
WES on a range of disorders, mostly neurological, have
reported a yield of around one in four, making it the
highest yield test yet in the clinical geneticist’s arma-
mentarium [10–12].
The cost of clinical-grade WES is high, typically >
US$4500 (higher when done as a child–parents trio),
with a long turnaround time of three months on aver-
age. These drawbacks are primarily driven by the inter-
pretation challenge. WES typically uncovers numerous
variants, and identifying the one causal variant can be
a challenge. Despite the development of several tools
that aid in the automation of prioritizing WES variants,
the requirement for manual inspection and expert ana-
lysis remains. In addition, there is a growing concern
about the potential of WES to reveal medically action-
able results that are unrelated to the original indication
for the test (secondary or incidental findings) and how
best to communicate them to patients [13].
An alternative approach to WES is gene panels in
which an assortment of genes deemed relevant to a
particular phenotype are sequenced in patients with
that phenotype. Such a focused analysis of a subset of
clinically relevant genes obviates or minimizes some of
the key challenges described above for WES [14, 15].
One key difficulty in the design of these panels is defin-
ing the appropriate list of genes for a given phenotype
owing to the remarkable variability of clinical presenta-
tions. Indeed, gene panels developed by different labs
for the same indication are seldom identical and the
discrepancy can be significant [16]. In this study, we
took a different approach whereby we relaxed the clin-
ical indication such that minimal clinical expertise is
required to order the appropriate panel; e.g., unusual
facial appearance will trigger testing for the Dysmor-
phology/Dysplasia panel, whereas acidosis will trigger
testing for the Inborn Errors of Metabolism panel. This
very inclusive design allowed us to define 13 very
broad clinical themes among which a set of ~3000
Mendelian genes (as of August 2013 when the assay
was designed) were distributed. We describe the suc-
cessful testing of this assay on more than 2300 patients
with diagnoses spanning the spectrum of medical and
surgical specialties. We implemented a multiplexing
strategy to run more than one sample on the high
throughput sequencer. This contributed to the reduc-
tion of the sequencing cost, which ultimately reduced
the final sample processing cost.Results
High analytical sensitivity and specificity of the
Mendeliome assay
We used 642 samples with known mutations to calculate
the analytical sensitivity of the Mendeliome assay. Over-
all analytical sensitivity was 79 % (507/642). The Mende-
liome assay missed 135 known mutations, 46 % (62/135)
of which were due to a design flaw, i.e., the disease gene
was not included in the panel appropriate for the disease
presentation. If these 62 cases were excluded (genes can
easily be added to the panel, see below), the overall
analytical sensitivity would increase to 87 % (507/580).
Based on these positive controls (580), sensitivity for sin-
gle nucleotide variants was found to be 93 % (398/428).
However, sensitivity for indels was lower at 72 %
(109/152). As expected for the semiconductor-based
ion torrent sequencing, the bias against indels was
not uniform but was largely sequence context-dependent,
especially around homopolymer regions [17]. In addition
to these positive controls, we used single nucleotide poly-
morphism (SNP) genotyping arrays (Affymetrix Axiom
GT1 chip with ~580,000 SNPs) coming from 21 patients
as a second method of testing the analytical sensitivity.
We compared the variants detected by SNP arrays with
those detected by the NGS technology for each sample.
From a total of 3319 SNPs lying within our target regions
of the panels, the resulting SNP sensitivity was about
95 %. Interestingly, we identified 30 extra SNPs that were
called by the assay but were not called with high confi-
dence on the chip. For analytical specificity, we used a pre-
determined quality score of 100 (this takes into account
strand bias, homopolymer errors, among others; see
“Materials and methods”). Analytical specificity was based
on the Sanger validation of 1078 variants called by the
assay. Sanger sequencing confirmed 93 % (819/881) of
single-nucleotide variants and 78 % (154/197) of indels
that met or were higher than that quality score.
High yield of the Mendeliome assay in the clinic
A total of 2357 patients representing a very wide range
of suspected genetic diseases were tested by the Mende-
liome assay (see Table 1 for the number of patients
tested on each panel). Only one panel was chosen per
patient based on the most prominent “primary clinical
feature” (see “Materials and methods”). The overall clin-
ical sensitivity — i.e., detection of a likely causal variant
that is subsequently confirmed by Sanger sequencing —
was 43 %. Table 1 also summarizes the clinical sensitivity
per panel as well as per clinical feature within each
panel. As expected, specialties with the highest referral
rate were neurology, dysmorphology, pediatric ophthal-
mology and immunology because of the nonspecificity
of the clinical presentation, extreme and genetic hetero-
geneity, and because a genetic cause is highly suspected
Table 1 Clinical sensitivities
Gene panel type Total patients run Overall clinical sensitivity Selected subgroup clinical sensitivity
Cardiovascular 243 28 % Cardiomyopathy 32 %
Congenital heart disease 10 %
Arrhythmias 31 %
Aneurysms 29 %
Deafness 147 54 % Hearing loss -
Dermatology 68 62 % Various dermatological features -
Dysmorphology-Dysplasia 354 38 % Skeletal dysplasia 45 %
Dysmorphism 32 %
Endocrinology 36 61 % Pituitary and thyroid disorders -
Gastroenterology 73 29 % Persistent jaundice -
Hematology 33 24 % Aplastic anemia -
Inborn errors of metabolism 122 59 % Metabolic disorders -
Neurology 524 40 % Syndromic DD/ID (recognizable syndromes) 47 %
Syndromic DD/ID NYD (not yet determined,
unrecognizable syndrome)
25 %
Structural brain (cerebral/cerebellar/brain stem)
and spinal malformations/anomaliesa
34 %
Non-syndromic DD/ID NYD (not yet determined,
unrecognizable)b
11 %
Neurodegenerative disorders 42 %
Coordinationc/movement disorders 69 %
Peripheral neuropathy 33 %
Myopathies/joint abnormalitiesd 56 %
PID 196 37 % Primary immunodeficiency disorders -
Pulmonology 36 36 % Chronic lung infection suspected cystic fibrosis -
Renal 107 57 % Glomerular/tubular disorders 41 %
Cystic kidney disease 63 %
Kidney malformation 69 %
Vision 418 52 % Retinal dystrophy (syndromic, non-syndromic, RP,
CRD, macular dystrophy, FEVR, GFS)
65 %
Cataract (syndromic and non-syndromic) 34 %
Aniridia 33 %
Microphthalmia/anophthalmia (with and without
coloboma)
30 %
Corneal dystrophy (CHED and all other subtypes) 40 %
Others 23 %
aPrimary microcephaly cases are included in this group
bNon-syndromic cases of autism/mental disorder and epilepsy are included under this group
cAtaxia cases secondary to cerebellar hypoplasia are included under the structural brain abnormalities group
dCases with arthrogryposis multiplex syndromes are included under the myopathies group
CHED corneal hereditary endothelial dystrophy, CRD cone-rod dystrophy, DD developmental delay, FEVR familial exudative vitreoretinopathy, GFS Goldmann-Favre
syndrome, ID intellectual disability, NYD not yet determined, PID primary immunodeficiency, RP retinitis pigmentosa
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we note a relatively high yield for the respective panels
of 40 %, 38 %, 52 %, and 37 % (Table 1). Specificity of
the presentation appeared to bear appreciably on the
clinical sensitivity of the assay. For example, with an ob-
jective evidence of skeletal dysplasia the sensitivity of theDymorphology/Dysplasia panel was 45 % compared with
32 % when any degree of dysmorphism was used as the
entry point. Similarly, the finding of a specific pattern of
neurological abnormality (e.g., muscular dystrophy and
neurodegenerative disorders) was associated with a
much higher sensitivity compared with non-syndromic
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(56 % and 42 % versus 11 %). Also consistent with this is
the finding that retinal dystrophies (almost always
Mendelian in etiology) were more likely to have positive
hits than the overall performance of the Vision panel
(65 % versus 52 %).
The Mendeliome assay performs favorably compared
with WES
The clinical sensitivity of our assay (43 %) is comparable
to the ~25 % reported by several large clinical WES
studies [10–12]. The Mendeliome assay is inherently
limited to established disease genes, so it will miss cases
caused by large structural variants and mutations in
novel genes, although the design is flexible and allows
for the addition of newly published disease genes as fre-
quently as needed, e.g., every six months. We have quer-
ied OMIM on 30 March 2015 and found <170 OMIM
genes that are not in the current design of the assay but
are eligible for inclusion due to high quality of the dis-
ease link. These can be spiked into the existing two tube
multiplex PCR. Even if we have to introduce these add-
itional genes as an additional PCR (rather than spike in)
for each panel, the cost of that additional PCR will be
< $10 since the product will be pooled with the product
of the other two tube multiplex PCR. Nonetheless, in
order to assess the magnitude of this limitation, we ran-
domly selected 213 cases that are negative by the Men-
deliome assay and processed them using molecular
karyotyping. Thirty-five of these were found to have
likely pathogenic de novo copy number variations
(CNVs) [18]. If we were to exclude these 35 cases, our
clinical sensitivity would increase slightly to 44 %. The
remaining 178 were processed using WES, and only
11 % (20/178) were found by WES to have a mutation in
a known gene that was missed by the Mendeliome assay.
Out of these 20 missed cases, the majority (n = 14, 70 %)
were due to a design flaw, i.e., the disease gene was not
included in the panel appropriate for the disease presen-
tation, and this can easily be fixed by the spike-in strat-
egy mentioned above. The remaining six cases represent
limitation of the analytical sensitivity of the NGS plat-
form we used in this study. On the other hand, we note
that our cohort included two patients who had had
negative diagnostic WES results prior to their enroll-
ment in the Mendeliome assay, and were found to have
likely causal mutations by the latter. These cases were
missed at the interpretation phase of WES analysis and
were solved by the Mendeliome assay likely because of
the smaller number of variants. The much smaller num-
ber of variants to be queried by the Mendeliome assay
versus WES also meant a much more rapid clinical in-
terpretation (average 20 min per panel versus 2–3 hours
per WES). This has markedly reduced the cost ofinterpretation on top of an already appreciable reduction
in running cost (24 panel samples were run per chip ver-
sus one WES per chip). The cost is estimated to be $150
per sample with a range of $75–150 per sample depend-
ing on the panel selected. Also relevant to cost reduction
is that we have had five couples who lost children with a
likely recessive disease but we had no access to DNA
from the deceased children. By running the appropriate
panel on both parents we were able to identify the likely
causal mutation at a much lower cost than the duo WES
design that would have been required to reach the same
conclusion. Thirty-one de novo mutations were identifi-
able as likely disease-causing heterozygous mutations in
relevant Mendelian genes, and their de novo status was
confirmed by Sanger sequencing of a single amplicon in
both parents.
The Mendeliome assay expands the clinical spectrum of
known genetic disorders
WES is frequently requested after one or more genes
deemed relevant to the patient’s clinical presentation
had been excluded by Sanger sequencing in hopes of
identifying a novel genetic cause. However, many WES
studies have highlighted the frequent encounter of
disease-causing mutations in known genes that would
not have been considered good candidates owing to the
marked discrepancy between their published phenotype
and the clinical presentation of the patient especially for
neurological and dysmorphic disorders, which are often
very heterogeneous clinically [19–21]. In a very recent
study, for example, we have shown that even in familial
cases that are carefully enriched for novel gene discovery
by excluding all relevant candidate genes by autozygome
analysis, 11 % of WES will reveal mutations in known
genes missed by the enrichment step because the pres-
entation was very atypical [22]. Indeed, in many patients
with disease-causing mutations identified by the Mende-
liome assay, the presentation was sufficiently different
from the published phenotype of the respective gene
that WES would have been pursued to establish the
diagnosis (Table 2). Some of the most dramatic examples
are a de novo EP300 mutation causing microcephalic
primordial dwarfism, a homozygous ZNF526 mutation
causing a novel Noonan-like phenotype, a homozygous
IFT122 mutation causing severe ocular anomalies and
unusual appendicular skeletal abnormalities, and a de
novo KMT2A mutation causing genital abnormalities in
an affected female, including absent uterus and vagina
with remarkable clitoromegaly (Table 2). On the other
hand, we have identified mutations in genes typically as-
sociated with multisystem disorders in patients with a
very limited phenotype, e.g., BBS4 mutation causing iso-
lated retinal dystrophy instead of Bardet-Biedl syndrome
(Table 2). Finally, we note the highly surprising finding
Table 2 Summary of clinical features observed in the atypical cases detected by gene panel testa
Mutation Observed phenotype compared with published phenotype(s)
Sample ID Gene name Type Status Origin Type of panel Published phenotype(s)




DG08RC00033 FGFR2 Missense HTZ De novo DD Craniosynostosis syndromes Craniofacial anomalies Upper eyelid coloboma
Sacrococcygeal tail





Thinning of the genu of
corpus callosum (with
Pfeiffer syndrome)
11DG0118 HRAS Missense HTZ De novo DD Costello syndrome Dysmorphic facies Corneal haziness
NM_005343.2: c.34G > A (p.Gly12Ser) Multiple joint dislocations Tracheomalacia and bronchomalacia




Valvular disease (mild TR, MR)
Thoracic dextroscoliosis Acanthosis nigricans
Metaphyseal dysplasia
NM_033150.2: c.3023G > T (p.Gly1008Val) Inguinal hernia
Myopia
09DG01603 TCOF1 Nonsense HMZ Inherited DD Treacher Collins syndrome 1 Underdevelopment
zygoma
Confirmed to be inherited as AR
Choanal atresia






10DG1847 BRAF Missense HTZ De novo DD Cardiofaciocutaneous
syndrome
Hypotonia Coarse face similar to Costello
syndrome
NM_004333.4: c.1789C > G (p.Leu597Val) Speech delay No cardiac defects
Acanthosis nigricans















Table 2 Summary of clinical features observed in the atypical cases detected by gene panel testa (Continued)
12DG0359 EP300 Nonsense HTZ De novo DD Rubinstein-Taybi
syndrome 2
None Atypical dysmorphic facies
Microcephalic primordial dwarfismNM_001429.3: c.1092C > A (p.Cys364*)
11DG2179 NFIX Nonsense HTZ Unknown DD Sotos syndrome type 2 Overgrowth Marfanoid habitus
(Father was not tested) GDD Normal bone age
NM_001271043.2: c.544G > T (p.Glu182*)
13DG0355 GNS Frameshift HMZ Inherited DD Mucopolysaccharidosis
type IIID
Mild coarse face Advanced RP
NM_002076.3: c.83del (p.Leu28Argfs*37) Mild hepatomegaly
Clear cornea
Skeletal manifestations
11DG2478 COL11A2 Missense HMZ Inherited DD Otospondylomegaepiphyseal
dysplasia
Epiphyseal dysplasia Hypoplastic optic nerve
NM_001163771.1: c.654 T > A (p.Tyr218*) Mitral valve prolapse and regurgitation
Deafness
14DG1212 IFT122 Splice site HMZ Inherited DD Cranioectodermal dysplasia 1 Nystagmus Iris and optic nerve coloboma
Metaphyseal dysplasia Microphthalmia
NM_052990.2:c.2042 + 2 T > C Duplicated thumb and big toe
Post-axial polydactyly
Very short tibiae compared with fibulae




NM_004560.3: c.1970G > A (p.Arg657His) Brachydactyly, type B1




08DG-00226 NSD1 Nonsense HTZ De Novo DD Sotos Syndrome 1 Dysmorphic facies No overgrowth
NM_022455.4: c.2058 T > A (p.Tyr686*) Thin corpus callosum, PVL
and colpocephaly on MRI
brain
10DG0615 CNNM4 Missense HMZ Parents not tested Vision Jalili syndrome LCA, retinal degeneration Retinal coloboma
NM_020184.3: c.734C > T (p.Ser245Leu) No dental anomalies
12DG0398 BBS4 Frameshift Compound
HTZ

















Table 2 Summary of clinical features observed in the atypical cases detected by gene panel testa (Continued)
14DG0073 ATRX Nonsense Hemizygous Inherited Neuro Mental retardation-hypotonic
facies syndrome, X-linked
Microcephaly RP
NM_000489.3:c.7156C > T (p.Arg2386*) GDD Optic disc coloboma
White matter changes
12DG1296 ALMS1 Frameshift HMZ Inherited Vision Alstrom syndrome Achromatopsia Lack of other features of Alstrom
syndrome (isolated achromatopsia)
NM_015120.4: c.1674delT (p.Pro559Leufs*37)
12DG1554 STXBP1 Missense HTZ De novo Neuro Epileptic encephalopathy,
early infantile, 4
Seizures Pigmentary retinal changes
NM_001032221.3: c.874C > T (p.Arg292Cys)
13DG1051 CDKL5 Nonsense HMZ Inherited Neuro Epileptic encephalopathy,
early infantile, 2
GDD Macrocephaly and overgrowth
NM_001037343.1: c.2854C > T (p.Arg952*) Facial dysmorphism similar to Sotos
syndrome but normal bone age and
negative NSD1 mutation
No seizures or regression
No abnormal movements
10DG2024 GTDC2 Missense HMZ Inherited Neuro Muscular dystrophy-
dystroglycanopathy (congenital
with brain and eye anomalies,
type A, 8)
None Isolated large occipital encephalocele
(POMGNT2) No polydactyly
NM_032806.5: c.473G > A (p.Arg158His) Neonatal death
12DG0133 HSD17B4 Missense HMZ Inherited Neuro D-bifunctional protein
deficiency
Neonatal seizures Normal brain MRI
No skeletal manifestations or stippling
NM_001199291.1: c.442C > G (p.His148Asp) No eye findings
No dysmorphism
10DG0415 ATN1 Missense HTZ De novo Neuro Dentatorubro-pallidoluysian None Early onset static encephalopathy
NM_001940.3: c.3178C > T (p.His1060Tyr) atrophy Novel molecular mechanism (point
mutation)
12DG0705 KIAA0196 Missense HTZ De Novo Neuro Ritscher-Schinzel syndrome Seizures Normal brain MRI
NM_014846.3: c.1669G > A (p.Ala557Thr) Spastic paraplegia 8, AD Speech delay and l
earning disability
No ataxia or spasticity
10DG0351 ADRA2B Nonsense HMZ Inherited Neuro Non-syndromic ID None Microcephaly
NM_000682.6: c.664C > T (p.Arg222*) GDD
12DG0532 ZNF526 Missense HMZ Inherited Neuro Mild non-syndromic ID None Novel Noonan like phenotype
GDDNM_133444.1: c.479A > C (p.Lys160Thr)
14DG0745 WDR45B Nonsense HMZ Inherited Neuro ID and microcephaly Primary microcephaly Epilepsy
















Table 2 Summary of clinical features observed in the atypical cases detected by gene panel testa (Continued)
13DG2156 WDR81 Nonsense HMZ Inherited Neuro Cerebellar ataxia, mental
retardation, and dysequilibrium
syndrome 2
Cerebellar hypoplasia Normal corpus callosum
NM_152348.3: c.133C > T (p.Gln45*) Prenatal onset complicated by neonatal
death
aAtypical case is defined as a case that has unusual clinical features, unusual mode of inheritance, a novel phenotype or lack of typical features
AD, autosomal dominant, AR, BBS Bardet-Biedl syndrome, DD Dysmorphia-Dysplasia panel, FTT failure to thrive, GDD global developmental delay, HMZ Homozygous, HTZ Heterozygous, ID intellectual disability, LCA,
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severe Treacher-Collins syndrome while the carrier par-
ents are completely normal clinically. Interestingly, this
mutation had been missed by direct Sanger sequencing
of TCOF1, most likely because the expectation was a
heterozygous peak on the sequence chromatogram given
the dominant nature of the disease. This is the first in-
stance of a recessive inheritance of TCOF1.
Improved annotation of the human variome
Large scale genomic studies offer opportunities to im-
prove the annotation of the human variome. This study,
in which more than 2300 well phenotyped human pa-
tients in a highly consanguineous population have been
specifically tested for established disease genes, offers
several advantages. First, we were able to confirm genes
that were only considered candidates because their can-
didacy was based on single mutations/families so their
status based on this study should be upgraded in OMIM
as such (e.g., ARL14EP, ZNF526, WDR45B, and WDR81).
Second, we have added 433 novel disease alleles from a
total of 788 variants, the largest to be reported in a single
study (Additional files 1 and 2). Interestingly, 22 variants
were concurrently added to the Human Gene Mutation
Database (HGMD) after submission of the manuscript.
These are in the HGMD release of 2015 and not in that of
2014. Third, the very large number of variants we identi-
fied in the course of this study represent an unprece-
dented resource on the Arab variome (nearly all patients
in this study were Arab in ethnicity), and this will be in-
valuable to the interpretation of clinical molecular genetic
tests on Mendelian genes in Arab patients since it will
help address the uncertainty surrounding the identifica-
tion of many Arab-specific or Arab-enriched variants
(Additional file 1). Fourth, the high degree of consan-
guinity allowed us to observe many variants in homozy-
gosity as a result of autozygosity. This is particularly
helpful when these variants were previously reported as
disease-causing because observing them in the homozy-
gous state at a relatively high population frequency
strongly argues against their purported disease link.
Additional file 3 includes 342 HGMD variants that ap-
peared at high frequency (minor allele frequency [MAF]
>1 %) in our in-house database, including 133 variants
with MAF >5 %. Of these variants with MAF >1 % in
our cohort, 137 are listed in the 1000 Genomes Project
with a MAF <1 %, highlighting the unique distribution
of variants in our population and the value it adds to
the annotation of the human variome. Furthermore, our
finding of previously reported disease genes that harbor
apparently inactivating mutations in the homozygous
state at a relatively high frequency and in patients who
lack the purported phenotype challenges their listing as
disease genes (e.g., CACNA1F, MYH8, and PRX1)although we acknowledge a potential role of such con-
founding factors as reduced penetrance.
Discussion
Genomics have ushered in a new era for clinical medi-
cine [23]. The ability to scan the entire genome (or its
coding part) for disease-causing mutations relatively free
of clinical bias has uncovered the limited sensitivity and
specificity of making diagnoses on clinical grounds only.
This was first apparent with the advent of array com-
parative genomic hybridization, which specifically targets
large genomic mutations. Subsequently, whole genome
sequencing (WGS) and WES confirmed the same pat-
tern. This raises the interesting question of whether all
patients with a suspected genetic diagnosis should have
WGS/WES as the initial diagnostic test [24]. Pending
data on the validity of this approach, one has to consider
some practical challenges. Cost remains a significant
hurdle that prevents most patients, especially in less
wealthy countries, from accessing WGS/WES. While the
running cost will continue to decrease, the challenge of
identifying a single causal variant from among tens of
thousands will remain formidable for the foreseeable fu-
ture [25]. In addition, debate still rages over the issue of
incidental findings, with changing guidelines reflecting
the strong and sound arguments made by camps on ei-
ther side of the debate, especially in pediatrics [26–28].
Gene panels that specifically target a disease relevant to
the patient’s presentation appear to address some of
these limitations but suffer from lack of uniformity in de-
sign and are typically too focused on a particular pheno-
type such that they may miss atypical presentations.
In this study, we sought to develop an assay that ad-
dresses the above-mentioned limitations. In the design
stage, we limited ourselves to genes that are very likely
to be disease-causing in a Mendelian context based on
the best available evidence in order to eliminate the un-
certainty surrounding the finding of variants in genes
not known to be linked to human diseases. We mainly
included genes whose pathogenicity was supported by
the presence of two pathogenic alleles. However, excep-
tions were made for genes with a single reported muta-
tion but are further supported by compelling mouse
data or positional mapping data. This is important be-
cause it has to be acknowledged that clinical WGS/WES
currently appears to saddle the divide between clinical
care and research [29]. If the Mendeliome assay is nega-
tive, it may be easier to prepare the patient for the possi-
bility of identifying a novel genetic cause by WGS/WES
that requires confirmation in a research setting. Unlike
currently available gene panels, we sought to be as inclu-
sive as possible to minimize the challenge of atypical
cases. For example, a gene for myopia presenting with
ectopia lentis would still be identified because virtually
Saudi Mendeliome Group Genome Biology  (2015) 16:134 Page 10 of 14every gene known to present with a prominent eye
phenotype was included in the Vision panel [30]. Indeed,
our analysis showed that only 3 % (62/2,357) of cases
may have been missed because the gene was not in-
cluded in the right panel and even this limitation can be
addressed through the spike-in design. Such broad and
inclusive design was particularly helpful in disease cat-
egories that are characterized by very high rates of het-
erogeneity. In addition to the Vision panel, we also note
the high rate of atypical cases identified by the Dysmor-
phology/Dysplasia, Neurology and Immunology panels,
although such cases were encountered in nearly all the
panels.
Conclusions
Our design brought about a dramatic reduction in cost
both in terms of reagents and interpretation. Although
clinical WES/WGS with exceptionally rapid turnaround
time has been reported, those were exceptional scenarios
that required a level of infrastructure and logistics well
beyond a typical healthcare facility [31]. On the other
hand, our turnaround time (one week from receiving the
sample to calling the candidate variants and three days
to confirm the variants by Sanger) can be offered rou-
tinely as a service to any healthcare provider. Therefore,
our test can be viewed as a potential first tier test that is
relatively inexpensive and rapid with a straightforward
consenting process. If negative, a more comprehensive
genomic test can be ordered as a second-tier test such
that the higher order complexities (cost, consent, etc.)
associated with this test can be confined to a smaller
number of individuals than it would otherwise be if it
were offered as a first-tier test.
Materials and methods
Human subjects
All families were enrolled under several King Faisal
Specialist Hospital and Research Centre institutional
review board-approved protocols (depending on the
phenotype), after signing a written informed consent.
These included: “Genetics of vision impairment in Saudi
Arabia” (RAC# 2070 023 Research Advisory Council),
“Genetics of craniofacial birth defects” (RAC# 2080 006),
“Characterization of peroxisomal biogenesis disorders in
Saudi Arabia” (RAC# 2080 033), “Genetics of OI in Saudi
Arabia” (RAC# 2090 035), and “Study of Mendelian
phenocopies of common diseases” (RAC# 2121 053). The
study was carried out in accordance with the declaration
of Helsinki.
Defining the Mendeliome
Patients with various hereditary disorders most often are
referred to the medical geneticist either through their
primary care provider or through a medical subspecialistwho attended to the most prominent clinical presenta-
tion (i.e., neurological, ophthalmology, skin, renal,
hematological, etc.). Therefore, we sought to design
our symptom/sign-based gene panels, collectively
known as the “Mendeliome” in a way that simulates
the way these patients present in clinical practice to
the respective specialty. Mendelian disorders are de-
fined as hereditary disorders caused by a single auto-
somal or X-linked gene. The OMIM database, which
currently contains about 4300 monogenic disorders as-
sociated with known molecular defects, represents the
most comprehensive source of such information on
monogenic disorders. Therefore, it was used as the pri-
mary source for gene identification. However, it was
manually curated to ensure that only genes with con-
firmed links to disease are included. It was also supple-
mented with additional data from PubMed, the
Genetic Testing Registry, and Gene Tests. As such, 13
gene panels which cover the spectrum of “pediatric
and adult” clinical genetic medicine were constructed.
Within each panel, genes were sorted based on the
most prominent sign/symptom with which they are
most likely to be associated upon presentation to clin-
ical care. This presentation may help the referring clin-
ician, and without requiring sophisticated knowledge
about these genes, decide on the appropriateness of
genetic testing using these gene panels. Since many
genetic disorders are as likely to present to several
medical specialties, we allowed for redundancy be-
tween the different panels (average 15 %) such that a
gene may be present in more than one panel.
Primer design and multiplexing assay development
We used 3070 genes covering over 4,000 Mendelian dis-
orders as annotated by OMIM up to August 2013 as a
basis for the design and synthesis of highly multiplexed
gene panels using Ion AmpliSeq Designer software (Life
Technologies, Carlsbad, CA, USA). Additional file 4
displays the list of genes, their corresponding panels, in-
formation about the used transcripts, physical positions,
and number of exons. Of these 3070 genes, 2826 are
already listed in the Genetic Testing Registry. Thirteen
panels encompassing nearly all of the OMIM genes were
defined broadly based on clinical disciplines with some
redundancy in gene content of individual panels. Primer
design was based on generating amplicons with an aver-
age length of 200 bp providing 90 % minimum coverage
of the coding DNA sequence, and, on average, 10 bp
flanking regions of associated exons. Additional file 5
contains all AmpliSeq primers used in the assay. Follow-
ing in silico design, coverage was assessed for compli-
ance with design criteria and manual processes applied
on a gene by gene basis to ensure adequate coverage
and resolve factors such as 3’ SNPs that could impact
Table 3 The results of applying filtering steps over all the variant files (including those with no relevant variant detected)
Panel Input Functional sites Public Pop. DBs SGP Pop. DB Quality Zygosity
Cardiovascular 746 338 76 26 9 2
Deafness 828 257 63 50 17 6
Dermatology 1113 271 71 41 17 5
Dysmorphology/Dysplasia 1529 369 80 43 15 2
Endocrinology 1129 326 61 42 19 5
Gastroenterology 362 190 60 20 6 1
Hematology 1474 324 79 39 18 3
Inborn Errors of Metabolism 1955 571 94 54 24 4
Neurology 2885 718 158 87 29 4
PID 633 309 111 22 6 1
Pulmonology 723 230 74 39 21 3
Renal 507 132 35 21 7 1
Vision 906 341 75 51 17 3
Total (averages) 1138 337 80 41 16 3
The table entries are the average number of variants per panel after applying the respective filter in the column title. The column titled ‘Input’ is the input without
applying any filter. The column titled ‘Functional sites’ is for the step of filtering intronic, UTR, synonymous variants. The column titled ‘Public Pop. DBs’ is for the
step of filtering variants based on the 1000 Genomes Project database. The column titled ‘SGP Pop. DBs’ is for the step of filtering variants based on the in-house
database. The column titled ‘Quality’ is for the step of filtering based on the quality criteria. The column titled ‘Zygosity’ is for the step of excluding
non-homozygous variants
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thesized and pooled into two multiplex reactions based
on PCR compatibility minimizing likelihood of primer–
primer interactions. Following synthesis, primer pools
were tested for coverage, recommended multiplexing
and other quality control metrics to ensure specifications
were met. Panels ranged from 96–758 genes with >90 %
coverage in 97–100 % of genes in each panel. Additional
file 6 shows information about the different panels and
related design information.
Library preparation and NGS
DNA samples (10 ng of each) were treated to obtain the
Ion Proton AmpliSeq library for one of the 13 gene
panels as appropriate. DNA was amplified using gene
panel Primer Pools, AmpliSeq HiFi mix (Thermo Fisher,
Carlsbad, CA, USA) and 10–15 amplification cycles.
PCR pools for each sample were combined and sub-
jected to primer digestion with FuPa reagent (Thermo
Fisher, Carlsbad, CA, USA). Pooled amplicons were then
ligated with universal adapters. After purification, librar-
ies were quantified by quantitative PCR and normalized
to 100 pM. Normalized libraries were barcoded (ligated
with 24 different Ion Xpress Brcode adapters) and
pooled in equal ratios for emulsion PCR (ePCR) on an
Ion OneTouch System. Following ePCR, templated Ion
Sphere particles were enriched using the Ion OneTouch
ES enrichment system enrichment system. Both ePCR
and enrichment procedures followed the manufacturer’s
instructions (Thermo Fisher, Carlsbad, CA, USA). Thetemplate-positive Ion PI Ion Sphere particles were proc-
essed for sequencing on the Ion Proton instrument
(Thermo Fisher, Carlsbad, CA, USA).
Data processing and bioinformatics analysis
The data of each run were analyzed through a multistep
pipeline. Additional file 7 summarizes the analysis work-
flow (pipeline), and the details of the variant filtration
sub-pipeline. The left side of Additional file 7 demon-
strates the basic steps of our variant detection workflow.
In the first step of this pipeline, the quality of the reads
is verified and regions of the reads with low quality (less
than 20) are trimmed out before alignment. The runs
with low yield after this quality check are excluded.
Additional file 8 shows the quality data for the runs per
panel at both Q0 and Q17 (results per panel is the aver-
age for all samples in the panel). In the second step, the
reads are aligned to the reference hg19 sequence. The
alignment program was tmap, which is distributed
within the Ion Torrent Suite (Thermo Fisher, Carlsbad,
CA, USA) [32]. Additional file 9 shows statistics about
the alignment and coverage related to the target regions
as well as the observed depth per panel (results per
panel is the average for all samples in the panel). The
observed depth after alignment ranges from 162× (for
the Neurology panel including 758 genes) to 840× (for
the Renal panel including 96 genes). It can be observed
from Additional files 8 and 9 that the data are of good
quality and the observed depth is very close to the ex-
pected depth. We can also conclude that it is possible to
Saudi Mendeliome Group Genome Biology  (2015) 16:134 Page 12 of 14increase the number of samples multiplexed per chip for
panels with low numbers of genes, such as the Renal
and Pulmonary panels, which reduces the cost without
affecting the quality. In the third step, the aligned reads
were processed for variant calling using the Torrent
Suite Variant Caller (TVC) program, which is tuned to
Ion Torrent data and considers quality scores and
manufacturer-specific details. In the subsequent step,
the variants are annotated using public knowledge data-
bases as well as in-house variant databases, using in-
house programs that extend the public Annovar pack-
age. The public databases include those available from
the Annovar package and other commercial datasets like
HGMD [33]. The in-house databases include collections
of disease-causing variants published by different Saudi
teams and aggregation of the variants produced by the
samples in this paper. In the final step of the pipeline,
the non-relevant variants are filtered out based on their
functional characteristics and their abundance in our
datasets. The right side of Additional file 7 illustrates the
details of the variant filtering process. Variants that are
less likely to play a functional role (intronic and syn-
onymous) and variants that were present in population
databases (e.g., in the 1000 Genomes Project database
with MAF >1 %) are filtered out. Furthermore, variants
that are frequent in our in-house database are also fil-
tered out; a variant with more than 20 occurrences were
considered frequent. (The cutoff of 20 occurrences has
been selected on test data to assure 100 % sensitivity.)
An individual base quality of 100 (using Phred-like score
produced by the Torrent Suite base caller) is also se-
lected to exclude low confident variants. The few
remaining variants are then analyzed based on relevance
of gene to phenotype, zygosity (when indicated), and
SIFT and PolyPhen scores (for missense variants). Table 3
shows the efficiency of our filtering strategy. It shows
that the subsequent filtering steps lead to a short list of
variants to be examined by domain experts. As the ta-
bles show and as expected, the larger the panel, the lar-
ger the list. It is also important to note that having
more samples included in the in-house database leads
to more filtration power and makes the list even
shorter. Ultimately, the recognized causal variant is
identified as pathogenic or likely pathogenic as defined
by the recent American College of Medical Genetics
and Genomics (ACMG) guidelines (“Standards and
guidelines for the interpretation of sequence variants: a
joint consensus recommendation of the American Col-
lege of Medical Genetics and Genomics and the Associ-
ation for Molecular Pathology”), and the extensive variant
data obtained by sequencing thousands of ethnically com-
parable patients (Saudis) was helpful in applying popula-
tion frequency as a reliable criterion for pathogenicity in
this study.Molecular karyotyping
Given that the Mendeliome assay is inherently limited to
established disease genes and will miss cases caused by
large structural variants, we randomly selected 213 cases
that are negative by the Mendeliome assay and processed
them using molecular karyotyping. The CytoScan HD
(Affymetrix) array was used for the majority of our
patients. This array platform contains 2.6 million markers
for CNV detection (Affymetrix), of which 750,000 are
genotype SNPs and 1.9 million are nonpolymorphic
probes, for the whole genome coverage. The analysis was
performed using the Chromosome Analysis Suite version
Cyto 2.0.0.195(r5758). Oligonucleotide probe information
is based on build 37 of the UCSC Genome Browser
(GRCh37/hg19) [34].
Briefly, 250 ng of genomic DNA was digested with the
restriction enzyme NspI and then ligated to an adapter,
followed by PCR amplification using a single pair of
primers that recognized the adapter sequence. The PCR
products were run on a 2 % Tris-borate-EDTA (TBE)
gel to confirm that the majority of products were be-
tween 150 and 2000 bp in length. To obtain a sufficient
quantity of PCR product for further analysis, all prod-
ucts from each sample were combined and purified
using magnetic beads (Agencourt AMPure, Beckman
Coulter, Beverly, MA, USA). The purified PCR products
were fragmented using DNase I and visualized on a 4 %
TBE agarose gel to confirm that the fragment sizes
ranged from 25 to 125 bp. The fragmented PCR prod-
ucts were subsequently end-labeled with biotin and
hybridized to the array. Arrays were then washed and
stained using a GeneChip Fluidics Station 450 and
scanned using an Affymetrix GeneChip Scanner 3000
7G. Scanned data files were generated using Affymetrix
GeneChip Command Console Software (version 1.2) and
analyzed with the Chromosome Analysis Suite.
The hidden Markov model available within the
Chromosome Analysis Suite software package was used
to determine the copy-number states and their break-
points. Thresholds of log2 ratio ≥0.58 and ≤ −1 were
used to categorize altered regions as CNV gains (amplifi-
cation) and copy number losses (deletions), respectively.
To minimize the detection of false-positive CNVs aris-
ing due to inherent microarray “noise”, only alterations
that involved at least 50 consecutive probes and that
were at least 500 kb in size were used to categorize al-
tered regions as CNV gains (amplification), whereas
those at least 200 kb in size were used to categorize copy
number losses (deletions).
We then proceeded to evaluate the CNVs detected in
our patients based on the ACMG standards and guide-
lines. The genic content in the CNV interval of all the
patients who had a molecular karyotype performed was
taken into consideration by seeking recent publications
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of CNVs that overlapped. To exclude aberrations repre-
senting common benign CNVs, all the identified CNVs
were compared with those reported in the Database of
Genomic Variants [35] and those reported in our own
database for individuals who have been classified as
normal.
De novo CNVs that met the size cutoff of 200 kb
for deletions and 500 kb for duplications (based on
the laboratory’s consideration of the performance
characteristics of the assay used) and were not found
in either parent were classified as pathogenic. How-
ever, this does not eliminate the possibility that
pathogenic CNVs exhibiting incomplete penetrance
or variable expressivity can be present in an un-
affected parent.
Whole exome sequencing and analysis
The remaining 178 were processed using WES. Each
DNA sample (100 ng) was treated to obtain the Ion
Proton AmpliSeq library. Briefly, DNA was amplified
in 12 separate wells using Exome Primer Pools, Ampli-
Seq HiFi mix (Thermo Fisher, Carlsbad, CA, USA) and
ten amplification cycles. All 12 PCR pools were com-
bined in one well and subjected to primer digestion
performing incubation with FuPa reagent (Thermo
Fisher, Carlsbad, CA, USA). Amplified exome targets
were ligated with Ion P1 and Ion Xpress Barcode
adapters. After purification libraries were quantified
using quantitative PCR with the Ion Library Quantifi-
cation Kit (Thermo Fisher, Carlsbad, CA, USA). The
prepared exome library was further used for emulsion
PCR on an Ion OneTouch System and templated Ion
Sphere particles were enriched using Ion OneTouch
ES, both procedures following the manufacturer’s
instructions (Thermo Fisher, Carlsbad, CA, USA). The
template-positive Ion PI Ion Sphere particles were
processed for sequencing on the Ion Proton instru-
ment (Thermo Fisher, Carlsbad, CA, USA). Approxi-
mately 15–17 Gb of sequence was generated per
sequencing run. Reads were mapped to UCSC hg19
[36] and variants identified using the Saudi Human
Genome Program (SHGP) pipeline.
Availability of data
All the variants generated on the participants of this
study, including disease and non-disease causing muta-
tions from the gene panels and from WES data, are
accessible through the Saudi Variome Database [37, 38].
Tabulated versions of the data are provided in Additional
files 1, 2, 3, 4, 5, 6, 8, and 9 and can be accessed through
[37, 38]. The exome files can be accessed through [37, 38].
The ClinVar accession numbers for the novel variants in
this paper are SCV000221340–SCV000221740.Additional files
Additional file 1: Table S1. List of unique variants that are disease-causing.
Additional file 2: Table S3. List of novel variants.
Additional file 3: Table S2. Frequent variants encountered in our study
that are designated as disease-mutation by HGMD. This table includes
342 HGMD variants that appeared at high frequency (MAF >1 %) in our
in-house database. Of these, 133 variants appeared at MAF >5 %. We also
observe that the MAF of 137 of them in the 1000 Genomes database is
less than 1 %. We also compared the HGMD release of 2013 with that of
2014. We found that in the 2014 release of HGMD, there are 16 new
variants with MAF >5 %.
Additional file 4: Table S7. List of genes included in the Mendeliome
assay.
Additional file 5: Table S8. Gene panel primers – contains all
AmpliSeq primers used in the assay.
Additional file 6: Table S4. Gene panel design information.
Additional file 7: Figure S1. Variant detection and analysis workflow.
On the left side we show the basic steps of our variant detection
workflow. The base calling step involves the transformation of signal data
into base space (A/C/G/T). The output of this step is an unaligned reads
in BAM format. The mapping is the process of aligning the reads to the
reference human genome (hg19). The output of this step is alignments
of all reads (BAM format). The variant calling involves the detection of
variations in the aligned reads. The variant filtration step involves the
exclusion of variants not related to the disease. On the right side, we
show the details of the variant filtration workflow. The first step involves
the exclusion of deep intronic variants (more than 20 bases far from the
exon terminals), UTRs, and non-frameshift indels. Then variants that are
frequent in public databases (the 1000 Genomes database) with
MAF >1 % are excluded. Variants that are also frequent in our in-house
database are also excluded (MAF >1 %). The remaining variants are then
filtered based on a score (>100) computed by Torrent Suite according to
different criteria like confidence of base calls, depth, and context bases.
The final step involves filtering based on zygosity (if the variant is
homozygous). Then domain experts evaluate the variants based on their
knowledge about the phenotype. The remaining short list of variants (if
not empty) is then sent to the Sanger team to validate the variants. The
numbers next to each step in the filtration is the average number of the
remaining variants after applying the next filtering step.
Additional file 8: Table S5. Sequencing quality data for the runs per
panel (entries are the average of all runs per panel).
Additional file 9: Table S6. Read alignment quality per panel (entries
are the average of all runs per panel).
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